

Andromeda Metals Limited ASX: ADN

ASX Announcement

9

10/431 King William Street Adelaide, SA 5000



ABN 75 061 503 375

HPA Project – Next phase of commercialisation underway

- Pilot scale testwork to optimise innovative flowsheet for continuous HPA production
- > 4N HPA samples to be produced for commercial evaluation by potential customers

Andromeda Metals Limited (ASX: **ADN**) (**Andromeda**, the **Company**) is pleased to announce that it is progressing the HPA Project to the next stage of commercialisation, by initiating pilot scale testwork for the continuous production of commercial samples of high-purity alumina (**HPA**) using Andromeda's proprietary process flowsheet.

This demonstration of continuous production and the generation of commercial samples is the next step in the commercialisation of Andromeda's HPA Project, following the recent announcement of the outcomes of the HPA Scoping Study¹. This study identified the establishment of a continuous pilot plant as a key next phase – for process flowsheet optimisation and the production of commercial samples for potential customers.

The pilot scale testwork will optimise Andromeda's innovative flowsheet to produce HPA in a continuous operation, moving beyond the batch processing previously used to produce HPA to 99.9985% purity².

Using refined kaolin from the Great White Project as feedstock, the pilot scale testwork is expected to produce 4N HPA (99.99% purity) in a variety of forms, which will then be used as commercial samples for evaluation by potential customers.

Andromeda's innovative process can produce HPA in a wide range of product forms, from amorphous to crystalline (gamma to alpha), and is flexible to produce HPA to suit individual customer and application needs.

The pilot scale testwork will inform future feasibility studies, as well as produce amorphous silicate byproduct material which will be further analysed and assessed for its potential value.

Sarah Clarke, Andromeda's Acting Chief Executive Officer said:

"We are excited to progress the HPA Project to the next stage of commercialisation, with the production of commercial samples of 4N HPA designed not only to demonstrate the technology in continuous process but also generate commercial samples for engagement with potential customers."

"The production of HPA represents a high-value, strategic growth opportunity that complements our premium kaolin product offering from the Great White Project. It also positions Andromeda to expand into the critical minerals sector, enhancing our product portfolio and exposure to emerging markets."

¹ Refer to ADN ASX dated 18 September 2025 titled *HPA Scoping Study demonstrates market-leading economics of Andromeda's innovative technology.*

² Refer to ADN ASX dated 1 May 2025 titled Andromeda Achieves HPA Breakthrough: Successful Production of 4N HPA & Validation of Novel Flow Sheet.



This announcement has been approved for release by the Board of Andromeda Metals Limited.

For more information about the Company and its projects, please visit our website, www.andromet.com.au or contact:

Manager, Investor Relations & Corporate Affairs

Patrick Sinclair T: 08 7089 9819 M: 0403 708 431

E: Patrick.Sinclair@andromet.com.au

FORWARD-LOOKING STATEMENTS

This document contains or may contain certain forward-looking statements and comments about future events, that are based on Andromeda's beliefs, assumptions and expectations and on information currently available to management as at the date of this document. Often, but not always, forward-looking statements can generally be identified by the use of forward-looking words such as "may", "will", "expect", "plan", "believes", "estimate", "anticipate", "outlook", and "guidance", or similar expressions. Such statements are only expectations or beliefs and are subject to inherent risks and uncertainties which could cause actual values, results or performance achievements to differ materially from those expressed or implied in this presentation. Where Andromeda expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and on a reasonable basis. No representation or warranty, express or implied, is made by Andromeda that the matters stated in this presentation will in fact be achieved or prove to be correct. Except as required by law, Andromeda undertakes no obligation to provide any additional or updated information or update any forward-looking statements, whether on a result of new information, future events, results or otherwise. Readers are cautioned against placing undue reliance on forwardlooking statements. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Andromeda, the directors, and management of Andromeda.